You are viewing the site in preview mode

Skip to main content

Table 4 Characteristics and recent treatments/conditions of patients with anti-IL-1therapy discontinuation for various reasons

From: Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

 AgeSexMutationDominant clinical features and the Reasons for Discontinuation of Anti-IL1 TreatmentDuration of Using Anti-IL-1 agentsRecent treatments/conditions
Patient 121FM694 V homozygousAmyloidosis Stage 5 CRD 11 g/day proteinuriaİncrease of proteinuria, Progression of CRDAnakinra/12 monthsRenal tx
Patient 228MM694 V heterozygous
M680I heterozygous		PAN+sacroiliitisActivation of PAN/high dose corticosteroidAnakinra/12 monthsSepsis-died
Patient 325MM694 V heterozygous
M680I heterozygous		Sacroiliitisrefractory low back pain
high BASDAI score		Canakinumab/4 monthsAnti-TNF
Patient 424MM694 V homozygousSacroiliitisrefractory low back pain
high BASDAI score		Canakinumab/6 monthsAnti-TNF
Patient 550MR761H homozygousSacroiliitis+polyarthritisRefractory arthritisCanakinumab/18 months (secondary non-responder)Tocilizumab
Patient 619MM680I homozygousPeripheral ArthritisRefractory arthritisAnakinra/3 monthsTocilizumab
Patient 749MM694 V homozygousAmyloidosis
Stage 4 CRD
2.5 g/day proteinuria		İncrease of proteinuriaCanakinumab/4 monthsTocilizumab
Patient 845FM694 V heterozygous Side effectAnakinra/2 yearsMultiple sclerosis-drug stop
  1. PAN polyarteritis nodosa, CRD Chronic Renal Disease, Renal tx renal transplant, (BASDAI) Bath Ankylosing Spondylitis Disease Activity Index, TNF Tumour necrosis factor, IL interleukin
Back to article page

Advances in Rheumatology

ISSN: 2523-3106